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Background: In mice MEOX2/TCF15 heterodimers are highly expressed in heart endothelial cells and are involved
in the transcriptional regulation of lipid transport. In a general population, we investigated whether genetic variation in
these genes predicted coronary heart disease (CHD).
Results: In 2027 participants randomly recruited from a Flemish population (51.0 % women; mean age 43.6 years), we
genotyped six SNPs in MEOX2 and four in TCF15. Over 15.2 years (median), CHD, myocardial infarction, coronary
revascularisation and ischaemic cardiomyopathy occurred in 106, 53, 78 and 22 participants. For SNPs, we contrasted CHD
risk in minor-allele heterozygotes and homozygotes (variant) vs. major-allele homozygotes (reference) and for haplotypes
carriers (variant) vs. non-carriers. In multivariable-adjusted analyses with correction for multiple testing, CHD risk
was associated with MEOX2 SNPs (P ≤ 0.049), but not with TCF15 SNPs (P ≥ 0.29). The MEOX2 GTCCGC haplotype
(frequency 16.5 %) was associated with the sex- and age-standardised CHD incidence (5.26 vs. 3.03 events per
1000 person-years; P = 0.036); the multivariable-adjusted hazard ratio [HR] of CHD was 1.78 (95 % confidence
interval, 1.25–2.56; P = 0.0054). For myocardial infarction, coronary revascularisation, and ischaemic cardiomyopathy, the
corresponding HRs were 1.96 (1.16–3.31), 1.87 (1.20–2.91) and 3.16 (1.41–7.09), respectively. The MEOX2 GTCCGC haplotype
significantly improved the prediction of CHD over and beyond traditional risk factors and was associated with similar
population-attributable risk as smoking (18.7 % vs. 16.2 %).
Conclusions: Genetic variation in MEOX2, but not TCF15, is a strong predictor of CHD. Further experimental studies
should elucidate the underlying molecular mechanisms.
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Endothelial cells lining the microvasculature constitute
the interface between the circulating blood and tissues
[1]. They differentiate to acquire the molecular, morpho-
logical and functional characteristics required for proper
organ function [1]. In the heart, endothelial cells play an
active role in the transport of fatty acids, the principal en-
ergy source for the continuously beating muscle [1, 2].
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fied a specific genetic signature for heart endothelial cells,
including MEOX2/TCF15 heterodimers as novel tran-
scriptional determinants [3]. This signature was largely
shared with skeletal muscle and adipose tissue endothe-
lium and was enriched in genes encoding fatty acid
transport-related proteins [3]. Using gain- and loss-of-
function approaches, we showed that MEOX2/TCF15 me-
diates fatty acid uptake in heart endothelial cells, in part, by
driving endothelial CD36 and lipoprotein lipase (LPL) ex-
pression and thereby facilitating fatty acid transport across
cardiac endothelial cells [3].
LPL is expressed at the luminal endothelial surface of ar-
teries and capillaries and hydrolyses circulating lipoproteins distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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and systemic [5] dysregulation of lipid metabolism and
endothelial dysfunction [6, 7] are hallmarks of coronary
atherosclerosis and long precede clinically overt dis-
ease. These observations suggest that genetic predis-
position plays an important role in the pathogenesis of
coronary heart disease (CHD) [6, 7]. In view of our recent
observations of enriched expression of MEOX2 and TCF15
in heart endothelial cells [3], we hypothesised that genetic
variation in the genes encoding these transcription fac-
tors might be associated with coronary risk. To test this
hypothesis, we analysed data accumulated since 1985
in a Flemish population study [8, 9].
Methods
Study population
The Flemish Study on Environment, Genes and Health
Outcomes (FLEMENGHO) complies with the Helsinki
declaration for research in human subjects and the Belgian
legislation for the protection of privacy (http://www.priva-
cycommission.be). The Ethics Committee of the Univer-
sity of Leuven approved the study. Recruitment for the
FLEMENGHO study started in 1985 [8, 9]. From August
1985 to November 1990, a random sample of the house-
holds living in a geographically defined area of Northern
Belgium was investigated with the goal to recruit an equal
number of participants in each of six strata by sex and age
(20–39, 40–59, and ≥60 years). All household members
aged 20 years or older were invited, if the quota of their
sex-age group had not yet been met. From June 1996 until
January 2004 recruitment of families continued using the
former participants (1985–1990) as index persons and
including teenagers. The participants were repeatedly
followed up. In all study phases, we used the same stan-
dardised methods to measure blood pressure and to admin-
ister questionnaires. The participation rate at enrolment
was 78.0 %. At each contact, participants gave or renewed
informed written consent.
Of 3343 enrolled participants, we excluded 1316 from
analysis, because blood stored in the biobank was exhausted
with no material left for genotyping (n = 521), because
of DNA degradation (n = 314), because at enrolment
they were less than 20 years old (n = 372), or because
one or more of the six MEOX2 or four TCF15 SNPs were
unavailable (n = 109). Thus, the number of participants
statistically analysed totalled 2027.
Measurements at baseline
Trained nurses measured the participants’ anthropomet-
ric characteristics and blood pressure. Body mass index
was weight in kilograms divided by the square of height
in meters. Blood pressure was the average of five consecu-
tive auscultatory readings obtained with a standard mercury
sphygmomanometer after participants had rested in thesitting position for at least 5 min. Hypertension was a
blood pressure of at least 140 mm Hg systolic or 90 mm
Hg diastolic, or use of antihypertensive drugs. The nurses
also administered a standardised questionnaire inquiring
about each participant’s medical history, smoking and
drinking habits, and intake of medications. Plasma glucose
and serum total and high-density lipoprotein (HDL) chol-
esterol and serum creatinine were measured by automated
methods in certified laboratories. Diabetes mellitus was a
fasting or random plasma glucose level exceeding 7.0 or
11.1 mmol/L, or use of antidiabetic agents [10].
Ascertainment of coronary events
FLEMENGHO received ethical approval. The database
was registered with the Privacy Commission. These legal
requirements being fulfilled, we could ascertain the vital
status of participants at annual intervals until 06 December
2012 via the Belgian Population Registry. In addition, we
could obtain the International Classification of Disease
codes for the immediate and underlying causes of death
from the Flemish Registry of Death Certificates. For 1853
participants, we collected information on the incidence of
non-fatal endpoints either via face-to-face follow-up visits
with repeated administration of the same standardised
questionnaire as used at baseline (n = 1521) or via a
structured telephone interview (n = 332). Follow-up data
were available from one visit in 360 participants, from two
in 304, from three in 436, and from four or more in 421
participants.
Trained nurses used the International Classification of
Diseases to code incident cases of CHD. Two investigators
blinded with regard to the genotypic results adjudicated all
coronary events against the medical records of general
practitioners or hospitals. Coronary events included sudden
death, fatal and non-fatal myocardial infarction, acute
coronary syndrome requiring hospitalisation, ischaemic car-
diomyopathy, and surgical or percutaneous coronary revas-
cularisation. In the outcome analyses, we only considered
the first event within each category.
Genotyping
Ethics approval and informed consent covered genotyp-
ing. After DNA extraction from peripheral blood [11],
SNPs were genotyped using the TaqMan® OpenArray™
Genotyping System (Life Technologies, Foster City, CA).
All DNA samples were loaded at 50 ng/mL and amplified
according to the manufacturer’s instructions. For analysis
of the genotypes, we used autocalling methods, as imple-
mented in the TaqMan Genotyper software version 1.3
(Life Technologies). Next, genotype clusters were eval-
uated manually with the sample call rate set above 0.90.
Sixteen duplicate samples gave 100 % reproducibility for all
64 SNPs on the custom made array, including the genes of
interest in the current article [12].
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(p22.1–p21.3). To select the MEOX2 SNPs to genotype,
we first reviewed all SNPs in this gene, including the
flanking regions, as available in the Illumina 1 M Duo
and OmniExpress arrays (San Diego, CA). We excluded
SNPs with a minor allele frequency of less than 1 % and
those that were in high linkage disequilibrium (r2 ≥ 0.80).
Next, based on the availability of SNPs on the TaqMan
OpenArray Genotyping System, we selected 12 tagging
SNPs (rs6946099, rs10777, rs7800473, rs13438001,
rs12056299, rs7787043, rs758297, rs4532497, rs10263561,
rs6959056, rs740566, rs1050290) that are in high linkage
disequilibrium (r2 ≥ 0.80) with 92 neighbouring SNPs
(Additional file 1: Figure S1 and Table S1), but were not in
high linkage disequilibrium (r2 < 0.80) with one another.
The 12 selected SNPs covered the entire gene with exten-
sion into the 3’ and 5’ flanking regions. We excluded six
SNPs with a successful genotyping call rate of less than
0.98. Finally, we retained six MEOX2 SNPs (rs10777,
rs12056299, rs7787043, rs4532497, rs6959056, and rs1050290)
in the analysis (Additional file 1: Table S2) that are in
linkage disequilibrium (r2 > 0.80) with 23 other SNPs
(Additional file 1: Table S1). TCF15 (6602 base pairs) maps
to chromosome 20p13. We genotyped five SNPs covering
the whole gene (rs282152, rs6116745, rs282162, rs3761308
and rs12624577), but excluded rs282152, because the SNP
call rate was less than 0.98 (Additional file 1: Figure S2).
Statistical analysis
For database management and statistical analysis, we used
SAS software, version 9.3 (SAS Institute, Cary, NC). For
comparison of means and proportions, we applied the
large sample z-test or ANOVA and Fisher’s exact, re-
spectively. We tested Hardy-Weinberg equilibrium in
unrelated founders, using the exact statistics available
in the PROC ALLELE procedure of the SAS package.
For analysis of single SNPs, we combined the least fre-
quent homozygous group with heterozygous subjects.
We tested linkage disequilibrium and reconstructed haplo-
types using the SAS procedures PROC ALLELE and PROC
HAPLOTYPE. To check for consistency, we repeated
haplotype construction accounting for pedigree information
using SHAPEIT version 2 (http://mathgen.stats.ox.ac.uk/
genetics_software/shapeit/shapeit.html [13]).
We compared the incidence of coronary endpoints in
relation to genetic variants, using (i) rates standardised by
the direct method for sex and age (<40, 40–59, ≥60 years)
and (ii) the cumulative incidence derived from Cox models
adjusted for sex and age. Next, we assessed the prognostic
value of the genetic variants in multivariable-adjusted Cox
regression. We checked the proportional hazard assump-
tion by applying a Kolmogorov-type supremum test as im-
plemented in the ASSESS statement of the PROC PHREG
procedure. To account for family clusters, we used thePROC SURVIVAL procedure of the SUDAAN 11.0.1
software (Research Triangle Institute, NC). In this pro-
cedure, non-independence among family members was
taken into account by including family as a random effect
along with other covariables as fixed effects. We analysed
genotypes and haplotypes using major allele homozygotes
and non-carriers as the reference group, respectively. We
adjusted P values for the associations between outcomes
and genetic variants, using the Benjamini and Hochberg
false discovery rate [14] according to the number of SNPs
retained in the analysis.
We computed the positive predictive value of the risk
carrying MEOX2 haplotype GTCCGC as (R × D)/([G/
100] × [R −1] + 1), where R is the multivariable-adjusted
hazard ratio, D is the incidence of CHD in the whole popu-
lation, and G is the prevalence of the GTCCGC haplotype
[15]. The attributable risk is given by ([R −1] × 100)/R and
the population-attributable risk by ([G/100] × [R −1] ×
100)/([G/100] × [R −1] + 1) [15]. Finally, we assessed the
power of the MEOX2 GTCCGC haplotype to predict CHD
over and beyond classical risk factors, using the integrated
discrimination improvement (IDI) and the net reclassifica-
tion improvement (NRI), as described by Pencina and col-
leagues for survival data [16].
Results
Baseline characteristics
All 2027 participants were White Europeans, of whom
1034 (51.0 %) were women. The study population consisted
of 332 singletons and 1695 related subjects, belonging to 49
single-generation families and 191 multi-generation pedi-
grees. Age averaged (±SD) 43.6 ± 14.3 years, blood pressure
125.0 ± 15.4 mm Hg systolic and 76.2 ± 9.5 mm Hg
diastolic, body mass index 25.7 ± 4.3 kg/m2, and total
cholesterol 5.49 ± 1.15 mmol/L. Among all participants,
486 (24.0 %) had hypertension, of whom 214 (44.0 %) were
on antihypertensive drug treatment, 33 (1.6 %) had dia-
betes mellitus, and 41 (2.0 %) reported a history of CHD.
Previous coronary complications included angiographic-
ally proven coronary stenosis, myocardial infarction, and
coronary revascularisation in 8 (0.4 %), 11 (0.5 %) and 22
(1.1 %) patients, respectively. Of 1034 women and 993
men, 277 (26.8 %) women and 328 (33.0 %) men were
smokers, and 168 (16.3 %) women and 418 (42.1 %) men
reported intake of alcohol. In smokers, median tobacco
use was 15 cigarettes per day (interquartile range, 10 to 20
cigarettes per day). In drinkers, the median alcohol con-
sumption was 14 g per day (8 to 26 g per day).
Table 1 lists the baseline characteristics of participants
according to CHD incidence. Most risk factors differed
in the expected direction between cases and non-cases.
However, compared with non-cases, the prevalence of
smoking was not different in patients with incident
CHD (29.6 % vs. 36.8 %; P = 0.13), while the prevalence
Table 1 Baseline characteristics of participants by incident CHD
Characteristic Non-cases Cases All
N° 1921 106 2027
N° with characteristics (%)
Women 1006 (52.4) 28 (26.4)‡ 1034 (51.0)
Current smoker 566 (29.6) 39 (36.8) 605 (29.9)
Drinking alcohol 565 (29.4) 21 (19.8)* 586 (28.9)
Diabetes mellitus 26 (1.4) 7 (6.6)‡ 33 (1.6)
Hypertension 432 (22.5) 54 (50.9)‡ 486 (24.0)
Treated hypertension 189 (9.8) 25 (23.6)‡ 214 (10.6)
History of CHD 30 (1.6) 11 (10.4)‡ 41 (2.0)
Mean of characteristic (±SD)
Age, years 42.8 ± 14.1 57.4 ± 11.3‡ 43.6 ± 14.3
Body mass index, kg/m2 25.6 ± 4.3 27.1 ± 3.9‡ 25.7 ± 4.3
Waist-to-hip ratio 0.84 ± 0.09 0.91 ± 0.08‡ 0.85 ± 0.09
Systolic blood pressure, mm Hg 124.5 ± 15.2 135.3 ± 15.8‡ 125.0 ± 15.4
Diastolic blood pressure, mm Hg 76.0 ± 9.4 78.6 ± 9.9† 76.2 ± 9.5
Heart rate, beats per minute 69.2 ± 9.5 69.9 ± 9.0 69.3 ± 9.5
Total cholesterol, mmol/L 5.46 ± 1.14 6.06 ± 1.15‡ 5.49 ± 1.15
HDL cholesterol, mmol/L 1.40 ± 0.39 1.16 ± 0.33‡ 1.37 ± 0.39
Total-to-HDL cholesterol ratio 4.21 ± 1.58 5.75 ± 2.30‡ 4.29 ± 1.66
Serum creatinine, μmol/L 90.2 ± 16.8 104.3 ± 19.4‡ 91.1 ± 16.8
Plasma glucose, mmol/L 5.03 ± 1.27 5.48 ± 2.29‡ 5.05 ± 1.35
HDL cholesterol refers to the serum concentration of high-density lipoprotein cholesterol. Diabetes mellitus was a fasting or random plasma glucose level exceeding 7.0 or
11.1 mmol/L, or use of antidiabetic agents. Hypertension was a blood pressure of ≥140 mm Hg systolic or ≥90 mm Hg diastolic or use of antihypertensive drugs. Significance
of the differences between non-cases and cases: * p ≤ 0.05; † p ≤ 0.01; ‡ p≤ 0.001
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P = 0.036). Heart rate at baseline was similar in partici-
pants without and with incident CHD (69.2 vs. 69.9 beats
per minute; P = 0.43).
Incidence of events
Over a median follow-up of 15.2 years (5th to 95th per-
centile interval, 5.7 to 27.1 years), 106 new coronary events
occurred, 24 fatal and 82 non-fatal. Coronary events com-
prised 12 fatal and 34 non-fatal myocardial infarcts and 7
sudden deaths. There were 78 patients who underwent
surgical (n = 29) or percutaneous (n = 56) coronary revas-
cularisation. Coronary events also included 5 fatal and 17
non-fatal cases of ischaemic cardiomyopathy.
Analyses of single SNPs in MEOX2 and TCF15
Additional file 1: Table S2 describes the position and the
SNPs retained in the analysis and the allele and genotype
frequencies in 825 unrelated founders. The six SNPs in
MEOX2 and the four SNPs in TCF15 complied with
Hardy-Weinberg equilibrium (0.30 ≤ P ≤ 0.80). In the
whole study population (Additional file 1: Table S3),
the frequencies of the minor alleles ranged from 21.1to 43.0 % for MEOX2 and from 9.6 to 38.5 % for
TCF15. The prevalence of minor allele homozygotes
ranged from 4.4 to 17.8 % for MEOX2, and from 0.7
to 15.9 % for TCF15.
The sex- and age-standardised incidence rates of coron-
ary events associated with the MEOX2 SNPs appear in
Additional file 1: Table S4. Compared with major allele
homozygotes, minor allele carriers experienced a higher
CHD incidence except for rs6959056. The sex- and age-
adjusted cumulative incidence of coronary events (Fig. 1)
showed significant association (P ≤ 0.012) with the MEOX2
SNPs except for rs1050290 (P = 0.058). There were no
differences in these estimates between homozygous and
heterozygous minor allele carriers (0.23 ≤ P ≤ 0.98) except
for rs12056299 (P = 0.014). For all coronary events com-
bined, the sex- and age-standardised incidence rates
(0.11 ≤ P ≤ 0.39) and the sex- and age-adjusted cumula-
tive incidence (0.11 ≤ P ≤ 0.71) did not differ among minor
allele carriers and major allele homozygotes of the four
TCF15 SNPs.
Next, we accounted for family clusters and adjusted
the hazard ratios for baseline characteristics, including
sex, age, body mass index, systolic pressure, the total-to-
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Fig. 1 CHD Incidence by genotype for six MEOX2 SNPs (Panels a-f). Estimates were standardised to the mean of the distributions of sex and age in the
whole study population. Vertical bars denote the standard error. P-values refer to the difference between minor allele carriers and major allele
homozygotes. Cumulative incidence did not differ between minor allele homozygotes and heterozygotes (0.23≤ P≤ 0.98 [a, c-f]), except for rs12056299
(P= 0.014 [b]). Median follow-up was 15.2 years. Tabulated data are the number of participants at risk by genotype at 6-year intervals
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hypertensive drug treatment. Compared with homozygotes
of the major allele, for rs10777, rs12056299, rs7787043,
rs4532497, and rs1050290, CHD risk was higher in minor
allele carriers, whereas the opposite was the case for
rs6959056 (Table 2). These findings remained consist-
ent with correction for multiple testing (Table 2) and
after excluding patients who had a history of CHD at
baseline (Additional file 1: Table S5).
For the four TCF15 SNPs, the multivariable-adjusted
hazard ratios modelling the CHD risk of minor allele car-
riers vs.major allele homozygotes did not reach significance
(0.75 ≤ hazard ratio ≤ 1.45; 0.072 ≤ P ≤ 0.52). However,
Additional file 1: Figure S3 shows interaction (P = 0.011)
between rs12624577 in TCF15 and rs4532497 in MEOX2.
Among C allele carriers of MEOX2 rs4532497, the hazard
ratio expressing the risk of the C allele relative to theTT genotype in TCF15 was 2.44 (95 % confidence inter-
val, 1.38–4.29; P = 0.0021), whereas among MEOX2 TT
homozygotes the corresponding hazard ratio was 0.75
(0.37–1.51; P = 0.42).
Analysis of MEOX2 haplotypes
Using the expectation-maximisation algorithm as imple-
mented in the PROC HAPLOTYPE procedure of the SAS
software version 9.3, three haplotypes of MEOX2 SNPs
had a frequency of over 10 % and were carried through in
the analysis. With letters referring to the alleles in
rs10777, rs12056299, rs7787043, rs4532497, rs6959056,
and rs1050290 in MEOX2, these haplotypes were
TCTTAT (27.5 %), TCTTGT (26.4 %), and GTCCGC
(16.5 %). For all coronary events, rates standardised for
sex and age (5.26 vs. 3.03 events per 1000 person-years;
Additional file 1: Table S6) and cumulative incidence
Table 2 Multivariable-adjusted hazard ratios for CHD by MEOX2 SNPs
SNP Event N° events/at risk Hazard ratio P PBH
Minor allele
carriers
Major allele
homozygotes
rs10777 GG + TG TT
All coronary events 59/911 47/1116 1.56 (1.06–2.29) 0.024 0.029
Myocardial infarction 31 22 1.75 (1.01–3.03) 0.045 0.054
Coronary revascularisation 42 36 1.42 (0.90–2.24) 0.13 0.14
Ischaemic cardiomyopathy 16 6 4.68 (1.86–11.77) 0.0011 0.0066
rs12056299 TT + CT CC
All coronary events 51/764 55/1263 1.68 (1.17–2.41) 0.0052 0.016
Myocardial infarction 28 25 2.05 (1.20–3.51) 0.0087 0.042
Coronary revascularisation 37 41 1.59 (1.02–2.49) 0.041 0.082
Ischaemic cardiomyopathy 14 8 3.37 (1.49–7.62) 0.0036 0.011
rs7787043 CC + TC TT
All coronary events 74/1111 32/916 1.72 (1.13–2.62) 0.011 0.023
Myocardial infarction 38 15 1.82 (1.02–3.27) 0.044 0.054
Coronary revascularisation 54 24 1.68 (1.02–2.77) 0.041 0.082
Ischaemic cardiomyopathy 16 6 2.22 (0.84–5.86) 0.11 0.20
rs4532497 CC + TC TT
All coronary events 66/1004 40/1023 1.80 (1.22–2.66) 0.0031 0.016
Myocardial infarction 33 20 1.88 (1.03–3.42) 0.040 0.054
Coronary revascularisation 50 28 1.88 (1.20–2.96) 0.0062 0.037
Ischaemic cardiomyopathy 14 8 1.97 (0.80–4.83) 0.14 0.20
rs6959056 AA + GA GG
All coronary events 59/1382 47/645 0.62 (0.42–0.92) 0.017 0.025
Myocardial infarction 27 26 0.52 (0.31–0.88) 0.014 0.042
Coronary revascularisation 46 32 0.71 (0.45–1.12) 0.14 0.14
Ischaemic cardiomyopathy 12 10 0.75 (0.33–1.70) 0.49 0.49
rs1050290 CC + TC TT
All coronary events 73/1194 33/833 1.50 (1.00–2.26) 0.049 0.049
Myocardial infarction 36 17 1.48 (0.81–2.70) 0.20 0.20
Coronary revascularisation 55 23 1.59 (0.99–2.56) 0.055 0.083
Ischaemic cardiomyopathy 16 6 1.97 (0.75–5.16) 0.17 0.20
Numbers of events do not add up, because only the first event in each category was analysed. Hazard ratios (95 % confidence interval) express the risk of minor
allele carriers vs. major allele homozygotes, account for family clusters, and were adjusted for baseline characteristics including sex, age, body mass index, systolic
pressure, total-to-HDL cholesterol ratio, smoking and drinking, and antihypertensive drug treatment. P and PBH indicate the significance of the hazard ratios without and
with Benjamini-Hochberg’s correction for multiple testing
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Figure S4), both before (P ≤ 0.012) and after adjustment
for multiple testing (P ≤ 0.036), showed significant associ-
ation with GTCCGC. In multivariable-adjusted analyses
(Table 3), GTCCGC carriers, compared to non-carriers, had
a 78 % higher CHD risk. The p-values before and after
correction for multiple testing were 0.0018 and 0.0054, re-
spectively. Myocardial infarction, coronary revascularisation
and ischaemic cardiomyopathy all showed significant asso-
ciation with the GTCCGC haplotype. These findings were
not materially different when we reconstructed haplotypesaccounting for pedigree information (Additional file 1:
Table S7) or after excluding patients who had a history of
CHD at baseline (Additional file 1: Table S8).
With adjustments applied as before, the positive predict-
ive value and the attributable and population-attributable
CHD risks associated with GTCCGC were 7.5, 43.1 and
18.7 %, respectively. For smoking, analysed as reference, the
corresponding estimates (unadjusted for genetic risk) were
7.2, 39.3 and 16.2 %, respectively. Table 4 shows that
in all participants and in those without CHD at entry,
adding the GTCCGC haplotype to the basic model
Table 3 Multivariable-adjusted hazard ratios for CHD by MEOX2 haplotypes
Haplotype Event N° events/at risk Hazard ratio P PBH
Carrier Non-carrier
TCTTAT
All coronary events 40/951 66/1076 0.73 (0.49–1.11) 0.14 0.21
Myocardial infarction 20 33 0.77 (0.42–1.41) 0.40 0.56
Coronary revascularisation 30 48 0.75 (0.47–1.19) 0.22 0.22
Ischaemic cardiomyopathy 6 16 0.56 (0.21–1.51) 0.25 0.25
TCTTGT
All coronary events 46/937 60/1090 0.90 (0.58–1.39) 0.63 0.63
Myocardial infarction 26 27 1.19 (0.67–2.11) 0.56 0.56
Coronary revascularisation 30 48 0.74 (0.46–1.20) 0.22 0.22
Ischaemic cardiomyopathy 9 13 0.59 (0.24–1.43) 0.24 0.25
GTCCGC
All coronary events 43/614 63/1413 1.78 (1.24–2.56) 0.0018 0.0054
Myocardial infarction 23 30 1.96 (1.16–3.31) 0.012 0.036
Coronary revascularisation 33 45 1.87 (1.20–2.91) 0.0058 0.017
Ischaemic cardiomyopathy 11 11 3.16 (1.41–7.09) 0.0053 0.016
Numbers of events do not add up, because only the first event in each category was analysed. Letters coding the haplotypes refer to the rs10777, rs12056299,
rs7787043, rs4532497, rs6959056 and rs1050290 alleles (see Additional file 1: Table S1 and S2). Haplotypes were reconstructed using the expectation-maximisation
algorithm as implemented in the PROC HAPLOTYPE procedure of the SAS software version 9.3. Hazard ratios (95 % confidence interval) express the risk associated
with carrying vs. not carrying a haplotype, account for family clusters, and were adjusted for baseline characteristics including sex, age, body mass index, systolic
pressure, total-to-HDL cholesterol ratio, smoking and drinking, and antihypertensive drug treatment. P and PBH indicate the significance of the hazard ratios without and
with Benjamini-Hochberg’s correction for multiple testing
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P ≤ 0.056) IDI and NRI.
Discussion
To our knowledge, our study is the first to relate in a
general population CHD incidence to genetic variation
in MEOX2 and TCF15, two transcription factors that are
highly expressed by cardiac endothelium and that in a
heterodimeric fashion interfere with cardiac energy me-
tabolism by driving endothelial CD36 and LPL expres-
sion, thereby facilitating fatty acid transport across the
cardiac endothelium [3]. The key finding of our current
study was that the risk of advanced CHD was associated
with genetic variation in MEOX2, as captured by six tag-
ging SNPs. On the other hand, genetic variation in TCF15,
coding for the heterodimeric partner of MEOX2, was not
associated with the incidence of coronary events. Nonethe-
less, the CHD risk associated with MEOX2 rs4532497 wasTable 4 Improvement in predicting CHD events by adding haplotyp
Study group Integrated discrimination improv
%Δ (95 % CI)
All (n = 2027) 0.81 (−0.02 to 1.65)
Free of CHD at entry (n = 1986) 1.15 (0.17 to 2.12)
%Δ is the percentage change (95 % confidence interval). The basic model includes t
cholesterol ratio, smoking and drinking, and antihypertensive drug treatment. The inte
slopes of the basic model and the basic model extended with the GTCCGC haplotype.
cases and cases. The net reclassification improvement is the sum of the percentages oconfined to TCF15 rs12624577 variant allele carriers, which
might reflect the known heterodimeric action picked up in
our experimental studies [3]. Although our current study
firmly established an association between CHD risk and
genetic variation in MEOX2, the molecular mechanisms
underlying this relation need further clarification in experi-
mental studies back translating our epidemiological find-
ings. For now, working hypotheses might be developed
along two lines respectively involving disturbed lipid hand-
ling [5, 17–19], a key mechanism in atherosclerosis, or
the involvement of MEOX2 in the angiogenic responses
to stressors [20–24] or in the migration or proliferation of
endothelial and vascular smooth muscle cells [25, 26].
A large-scale genome-wide association study identified
46 significant lead SNPs associated with CHD. Twelve
showed a significant association with a lipid trait. Vari-
ation in the MEOX2 gene was not among these SNPs, but
LPL (rs264) was [27]. LPL catalyses the hydrolysis ofe GTCCGC to the basic model
ement Net reclassification improvement
P %Δ (95 % CI) P
0.056 21.7 (2.5 to 40.8) 0.026
0.021 24.9 (4.7 to 45.3) 0.016
he baseline covariables sex, age, body mass index, systolic pressure, total-to-HDL
grated discrimination improvement is the difference between the discrimination
The discrimination slope is the difference in predicted probabilities between non-
f participants correctly reclassified to non-cases and cases
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lomicrons and very low density lipoproteins at the capil-
lary endothelial cell surface, providing free fatty acids and
glycerol as energy source for tissues [19]. Genetic variation
in LPL is associated with the levels of circulating LPL activ-
ity [5], the plasma concentration of triglycerides [5, 18] and
HDL cholesterol [5, 18] and in some [17], albeit not all
[18], studies with the risk of CHD. Parenchymal cells in
adipose, skeletal and cardiac muscle widely express LPL
throughout the body [19]. Cardiac endothelial cells have a
particular expression profile including MEOX2, a gene
that facilitates fatty acid transport into and through heart
endothelial cells. As for genetic variation in LPL [5, 18],
we hypothesised that dysregulation of lipid transport in
cardiac endothelial cells might increase CHD risk. Import-
ant in this regard is that in our current study, in contrast
to the studies on genetic variants of LPL [5, 18], we did
not find any association of the circulating lipid levels with
MEOX2 variants (data not shown), pointing to a local cor-
onary rather than a systemic underlying mechanism.
Moving to the second hypothetical pathophysiological
pathway, MEOX2 is also known as growth arrest-specific
homeobox (GAX) [20], During embryonic development,
the three muscle lineages express GAX [21]. In adult life,
vascular smooth muscle cells also express GAX [21]. Mito-
genic stimuli, such as platelet-derived growth factor and
angiotensin II or injury of the endothelium [22], inhibit
GAX expression, whereas growth arrest signals, such as
serum deprivation of cultured cells, enhance its expression
and negatively regulate the cell cycle [23]. Observations in
transfected cells also point to MEOX2 as a potentially im-
portant regulatory gene inhibiting not only the angiogenic
response of endothelial cells to pro-angiogenic factors, but
also their response to chronic inflammatory stimulation
that normally activates NF-κB [24]. Inflammatory pathways
identified in a network analysis of 233 candidate genes play
key roles in development of coronary atherosclerosis [27].
These observations [22–24, 27] may offer an alternative ex-
planation why in our current study coronary risk was asso-
ciated with genetic variation in MEOX2. Chen and Gorski
did an in silico search for micro-RNA binding sites in the
GAX 5’UTR and identified consensus sites for multiple can-
didate micro-RNAs, of which only miR-130a was expressed
in proliferating endothelial cells [26]. miR-130a was largely
responsible for the down-regulation of GAX expression in
response to mitogens and pro-angiogenic factors and
antagonised the antiangiogenic activity of GAX [26].
To our knowledge, previously published GWAS results
did not demonstrate association between coronary heart
disease and MEOX2. However, these GWAS studies
relied on comparing cases and controls drawn from hetero-
geneous sources [27–29] or on a retrospective cross-
sectional analysis of patients referred for coronary angiog-
raphy [30]. GWAS case–control studies offer theopportunity for searching for association between CHD
and densely distributed SNPs across the whole genome in
large numbers of patients and controls. Such studies re-
quire significance levels of 10-6 to 10-8. In contrast, our
study was prospective and population-based and tested a
prior hypothesis involving only six SNPs in MEOX2 and
four in TCF15. We did therefore not rely on such extreme
P-values, but applied the Benjamin-Hochberg approach for
multiple testing. Admittedly, our sample size was smaller
than in the GWAS studies. This is particularly relevant for
the interaction between MEOX2 rs4532497 and TCF15
rs12624577 (Additional file 1: Figure S3), a finding, which
although in line with our experimental findings [3] can only
be considered as hypothesis generating. Future population-
based research projects might address this issue.
We performed the annotation of the genomic context
surrounding the SNPs retained for MEOX2, based on
the data of the ENCODE project (http://www.genome.gov/
encode). As shown in Additional file 1: Table S1, rs10777
and rs1050290 map into the 3’UTR and 5’UTR regions, re-
spectively, whereas rs12056299, rs7787043, rs4532497 and
rs6959056 are in the first intron of MEOX2. Moreover, ac-
cording to Ensemble 75 annotation (http://www.ensem-
bl.org/Homo_sapiens/Info/Annotation) and GENCODE 22
(http://www.gencodegenes.org/releases/22.html), rs4532497
and rs6959056 also map into the ENSG00000237070
(AC005550.3) antisense non-protein coding gene. In par-
ticular, rs4532497 maps into intron 1, whereas rs6959056
maps into exon 4 of ENSG00000237070. rs6959056 and
rs1050290 fall into a promoter regulatory region (ENST
00000622287) both in human umbilical vein endothelial
cells and in human dermal fibroblasts, where MEOX2 is
expressed. Further functional studies are needed to investi-
gate the possible modulation of MEOX2 expression. More-
over, rs6959056 in exon 4 of the non-coding transcript
ENST00000451240 could affect gene function, although no
information on the ENSG00000237070 gene is currently
available.
TCF15, also known as Paraxis, is a member of the Twist
subfamily of basic helix-loop-helix transcription factors that
regulate specification of mesodermal derivatives during ver-
tebrate embryogenesis [31]. TCF15 primes pluripotent cells
for differentiation [32]. During dermomyotome formation
in Xenopus laevis, TCF15 directly activates the expression
of MEOX2 [31]. Our experimental studies demonstrated
that the MEOX2/TCF15 heterodimer facilitates the trans-
port of fatty acids across cardiac endothelial cells and that
in mice haplodeficiency in these genes results in impaired
contractility of cardiomyocytes and heart failure [3]. In our
population study, we therefore also searched for association
between the incidence of well-documented heart failure
and variation in the MEOX2 and TCF15 genes. Several rea-
sons may explain why such associations were not detected.
Indeed, heart failure is a heterogeneous disease caused by a
Yang et al. BMC Genetics  (2015) 16:116 Page 9 of 10multitude of instigators, including ischaemic or valvular
heart disease, comorbidities, or risk factors such as hyper-
tension. Moreover, the diagnosis of heart failure depends
on the clinical interpretation of a combination of signs and
symptoms, that are difficult to recognise [33, 34].
The present study must be interpreted within the con-
text of some potential limitations. First, even though our
analysis was hypothesis-driven based on published evi-
dence from experimental studies [3], we adjusted signifi-
cance levels for multiple testing according to the number
of SNPs tested, using the Benjamini and Hochberg false
discovery rate [14]. Even applying the most stringent ap-
proach described by Bonferroni did not remove the signifi-
cance for rs12056299 (P = 0.031), rs45324977 (P = 0.019)
and haplotype GTCCGC (P = 0.0054) in relation to CHD.
On the other hand, we did not consider applying a correc-
tion for multiple testing based on the four coronary end-
points. Indeed, such events are highly correlated. Multiple
testing is therefore not indicated, because each new test
does not provide an independent opportunity for a type-I
error [35]. Second, although an observational study cannot
prove causation, the Bradford-Hill criteria [36] suggest
that the association between coronary risk and genetic
variation in MEOX2 might be causal, taking into account
(i) the strength and consistency of the association across
different SNPs; (ii) temporality, genetic variability preced-
ing the event; (iii) plausibility based on the experimental
studies [3]; and (iv) the analogy observed with genetic
variability in LPL [5, 17–19]. Third, only few genes regu-
lated by MEOX2 and TCF15 are currently known. In this
regard, it is important to note that we noticed that of the
genes overexpressed in cardiac endothelial cells, those
most upregulated included genes involved in lipid homeo-
stasis, including LPL [3]. Finally, as is common in many
population studies, follow-up was inconsistent, with vary-
ing numbers of follow-up visits across participants. In
addition, participants without blood sample, compared
with those included in the analyses (Additional file 1:
Table S9), were slightly older (49.4 vs. 43.6 years) and had
a higher systolic blood pressure (129.5 vs. 125.0 mm Hg),
resulting in a higher prevalence of hypertension (40.0 vs.
24.0 %). We cannot ascertain whether these factors might
have biased our analyses.
The clinical implications of our current findings can
be gauged by the observation that the attributable and
population-attributable CHD risks were similar for the
MEOX2 GTCCGC carrying state and smoking. Several
investigators proposed the use of genetic risk scores based
on genome-wide association studies to stratify for the prob-
ability of CHD [37, 38]. In the Framingham Heart Study
[37], a score consisting of 13 SNPs did not refine the pre-
diction of CHD or cardiovascular disease, but led to modest
improvements in risk reclassification. In contrast, in the
Rotterdam Study [38], a score based on 152 SNPs wasassociated with incident CHD, but did not enhance risk
prediction. SNP discovery based on prevalent rather than
incident CHD might explain these discrepancies [38]. In
our current study, genetic variation in MEOX2 improved
IDI and NRI over and beyond the basic model including
traditional CHD risk factors.
Conclusion
Our current study based on a predefined hypothesis gener-
ated by data from our experimental studies [3], identified
genetic variation in the transcription factor MEOX2 gene as
a novel risk factor for CHD in a white population. However,
further experimental studies are required to back-translate
our epidemiological observations into underlying molecular
mechanisms. Elucidation of these pathways might reveal
new targets for the prevention and treatment of CHD.
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